Mcl-1 is a novel target of miR-26b that is associated with the apoptosis induced by TRAIL in HCC cells

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Jiang, Chunlin ^a   Long, Jianting ^a   Liu, Baoxian ^a   Xie, Xiaoyan ^a   Kuang, Ming ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 26B; PROTEIN MCL 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; MCL1 PROTEIN, HUMAN; MIRN26A MICRORNA, HUMAN; TNFSF10 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BIOINFORMATICS; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MTT ASSAY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICRORNAS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84930644605     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/572738     Document Type: Article

References (37)

1. R. Siegel,D.Naishadham, andA. Jemal, "Cancer statistics, 2012," CA Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10-29, 2012.
2. Z. Xu, G. Huang, W. Gong et al., "FXR ligands protect against hepatocellular inflammation via SOCS3 induction," Cellular Signalling, vol. 24, no. 8, pp. 1658-1664, 2012.
3. R. Zampino, A. Marrone, L. Restivo et al., "Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations," World Journal of Hepatology, vol. 5, no. 10, pp. 528-540, 2013.
4. T. K. Seow, R. C. M. Y. Liang, C. K. Leow, and M. C. M. Chung, "Hepatocellular carcinoma: from bedside to proteomics," Proteomics, vol. 1, no. 10, pp. 1249-1263, 2001.
5. L.W.Thomas, C. Lam, andS.W.Edwards, "Mcl-1; themolecular regulation of protein function," FEBS Letters, vol. 584, no. 14, pp. 2981-2989, 2010.
6. T. Zhang, S. Qu, Q. Shi, D. He, and X. Jin, "Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1," International Journal of Molecular Sciences, vol. 15, no. 2, pp. 3154-3171, 2014.
7. S. J. Leuenroth, P. S. Grutkoski, A. Ayala, and H. H. Simms, "The loss of Mcl-1 expression in human polymorphonuclear leukocytes promotes apoptosis," Journal of Leukocyte Biology, vol. 68, no. 1, pp. 158-166, 2000.
8. W. J. Placzek, J. Wei, S. Kitada, D. Zhai, J. C. Reed, and M. Pellecchia, "A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy," Cell Death and Disease, vol. 1, no. 5, article e40, 2010.
9. W. Sieghart,D.Losert, S. Strommer et al., "Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy," Journal of Hepatology, vol. 44, no. 1, pp. 151-157, 2006.
10. J. Michels, F. Obrist, G. Kroemer et al., "MCL-1 dependency of cisplatin-resistant cancer cells," Biochemical Pharmacology, vol. 92, no. 1, pp. 55-61, 2014.
11. X. Li, X. Zeng, J. Sun et al., "Imperatorin induces Mcl-1 degradation to cooperatively trigger Bax translocation and Bak activation to suppress drug-resistant human hepatoma," Cancer Letters, vol. 348, no. 1-2, pp. 146-155, 2014.
12. D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function," Cell, vol. 116, no. 2, pp. 281-297, 2004.
13. J. Winter, S. Jung, S. Keller, R. I. Gregory, and S. Diederichs, "Many roads to maturity: microRNA biogenesis pathways and their regulation," Nature Cell Biology, vol. 11, no. 3, pp. 228-234, 2009.
14. Y. Zhao, Y. Li, G. Lou et al., "MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells," PLoS ONE, vol. 7, no. 6, Article ID e39102, 2012.
15. A. M. Cheng, M. W. Byrom, J. Shelton, and L. P. Ford, "Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis," Nucleic Acids Research, vol. 33, no. 4, pp. 1290-1297, 2005.
16. Y.-X. Song, Z.-Y. Yue, Z.-N. Wang et al., "MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation," Molecular Cancer, vol. 10, article 1, 2011.
17. E. T.Verghese, R. Drury, C. A. Green et al., "MiR-26b is downregulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion," The Journal of Pathology, vol. 231, no. 3, pp. 388-399, 2013.
18. C. Zhang, J. Tong, and G. Huang, "Nicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA-26b in colorectal cancer cells," PLoS ONE, vol. 8, no. 7, Article ID e69963, 2013.
19. K. J. Livak and T. D. Schmittgen, "Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method," Methods, vol. 25, no. 4, pp. 402-408, 2001.
20. C.Chen,D.A. Ridzon,D.H. Lee et al., "Real-timequantification of microRNAs by stem-loop RT-PCR," Nucleic Acids Research, vol. 33, no. 20, article e179, 2005.
21. S. J. Tong, J. Liu, X. Wang, and L. X. Qu, "microRNA-181 promotes prostate cancer cell proliferation by regulating DAX-1 expression," Experimental andTherapeutic Medicine, vol. 8, no. 4, pp. 1296-1300, 2014.
22. P. Ethiraj, K. Veerappan, B. Doraisami, and S. Sivapatham, "Synergistic anti-carcinogenic effect of interferon-β with cisplatin on human breast adenocarcinoma MDA MB231 cells," International Immunopharmacology, vol. 23, no. 1, pp. 222-228, 2014.
23. X.-T. Liang, K. Pan, M.-S. Chen et al., "Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma," Journal of Gastroenterology and Hepatology, vol. 26, no. 3, pp. 544-549, 2011.
24. B. Wang, Z. Ni, F. He et al., "The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells," Molecular Cancer, vol. 13, no. 1, article 98, 2014.
25. C. Thallinger, M. F. Wolschek, H. Maierhofer et al., "Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of Mcl-1 antisense oligonucleotides with low-dose cyclophosphamide," Clinical Cancer Research, vol. 10, no. 12, part 1, pp. 4185-4191, 2004.
26. J. T. Opferman, H. Iwasaki, C. C. Ong et al., "Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells," Science, vol. 307, no. 5712, pp. 1101-1104, 2005.
27. C. Thallinger, M. F. Wolschek, V. Wacheck et al., "Mcl-1 antisense therapy chemosensitizes humanmelanoma in a SCID mouse xenotransplantation model," Journal of Investigative Dermatology, vol. 120, no. 6, pp. 1081-1086, 2003.
28. S.-H. Wei, K. Dong, F. Lin et al., "Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targetingMcl-1 gene in pancreatic carcinoma cell," Cancer Chemotherapy and Pharmacology, vol. 62, no. 6, pp. 1055-1064, 2008.
29. V. Y. Shin and K. M. Chu, "MiRNA as potential biomarkers and therapeutic targets for gastric cancer," World Journal of Gastroenterology, vol. 20, no. 30, pp. 10432-10439, 2014.
30. L. H. Ren, W. X. Chen, R. H. Shi et al., "MicroRNA-183 promotes proliferation and invasion in oesophageal squamous cell carcinoma by targeting programmed cell death 4," British Journal of Cancer, vol. 111, no. 10, pp. 2003-2013, 2014.
31. S. L. Lei, H. Zhao,H. Yao et al., "Regulatory roles of microRNA-708 and microRNA-31 in proliferation, apoptosis and invasion of colorectal cancer cells," Oncology Letters, vol. 8, no. 4, pp. 1768-1774, 2014.
32. M. Pichler, A. L. Ress, E. Winter et al., "MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients," British Journal of Cancer, vol. 110, no. 6, pp. 1614-1621, 2014.
33. Y. Qin, X. Dang, W. Li, and Q. Ma, "miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer," Oncology Research Featuring Preclinical and Clinical CancerTherapeutics, vol. 21, no. 6, pp. 353-363, 2014.
34. J. Hou, L. Lin, W. Zhou et al., "Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma," Cancer Cell, vol. 19, no. 2, pp. 232-243, 2011.
35. G. Xu, C. Shi, C. Ji et al., "Expression of microRNA-26b, an obesity-related microRNA, is regulated by free fatty acids, glucose, dexamethasone and growth hormone in human adipocytes," Molecular Medicine Reports, vol. 10, no. 1, pp. 223-228, 2014.
36. J. Li, X. Li, X. Kong, Q. Luo, J. Zhang, and L. Fang, "MiRNA-26B inhibits cellular proliferation by targeting CDK8 in breast cancer," International Journal of Clinical and Experimental Medicine, vol. 7, no. 3, pp. 558-565, 2014.
37. G.Shen, Y. Lin,X.Yang, J. Zhang, Z. Xu, andH. Jia, "MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X," BMC Cancer, vol. 14, article 393, 2014.